Tempus to Acquire Personalis for $1.5B, Integrating MRD into AI Oncology Platform
PSNL has more than doubled off its 52-week low of $3.84 on elevated volume (1.9× avg).
Summary
Tempus AI will acquire Personalis for $1.5 billion in stock, combining Personalis' MRD technology with Tempus' AI platform and commercial scale. The deal values Personalis at $16.25 per share, a 28% premium to the unaffected 30-day VWAP, and is expected to close in late 2026 or early 2027.
Key Events · M&A and Partnerships · PSNL
-
Acquisition by Tempus AI
Tempus AI will acquire all outstanding Personalis shares not already owned by Tempus for $16.25 per share, representing a total enterprise value of $1.5 billion. Consideration is 100% Tempus stock with a floating exchange ratio capped at 0.3356; Tempus may elect to pay up to 50% in cash.
-
Premium to Market
The $16.25 per share offer represents a 6% premium to the July 18 closing price and a 28% premium to the unaffected 30-day volume-weighted average price.
-
Strategic Rationale
The acquisition integrates Personalis' NeXT Personal MRD test into Tempus' AI-enabled precision oncology platform, expanding Tempus' reach across the cancer care continuum and targeting a $20 billion MRD market.
-
Preliminary Q2 2026 Results
Personalis reported preliminary Q2 revenue of $22.4 million and delivered 10,384 clinical tests, a 33% increase quarter-over-quarter, indicating accelerating commercial momentum.
Analysis · PSNL · Industrial Applications And Services
Tempus AI is acquiring Personalis for $16.25 per share in a $1.5 billion all-stock deal, a 6% premium to the last close and 28% above the unaffected 30-day VWAP. The merger brings Personalis' industry-leading MRD test directly into Tempus' commercial infrastructure and AI platform, targeting a $20 billion market. Personalis shareholders will receive Tempus stock at a floating exchange ratio capped at 0.3356, with Tempus retaining an option to pay up to 50% in cash. The deal, approved by both boards, is expected to close in late 2026 or early 2027 pending shareholder and regulatory approvals. Personalis also reported preliminary Q2 revenue of $22.4 million and a 33% sequential jump in clinical test volumes, signaling accelerating commercial traction ahead of the merger.
At the time of this filing, PSNL was trading at $14.43 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $3.84 to $16.39. This filing was assessed with positive market sentiment and an importance score of 10 out of 10.